VITASPRING BIOMEDICAL CO. LTD. (VSBC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 01-31. Amounts in USD.

Revenue Quarterly

-1.5M 0 1.5M 3M 4.5M Q2 '22: 1.4M Q3 '22: 200K Q4 '22: 3.5M Q1 '23: 1.5M Q2 '23: 0 Q3 '23: 0 Q4 '23: -1.5M Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q3 '26: 0 Q4 '26: 0 Q1 '27: 0 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Gross Profit Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q4 '19: 2.3K Q1 '20: 6.3K Q2 '20: 3.5K Q3 '20: 3.5K Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 112.2K Q1 '22: 239.8K Q2 '22: 341.2K Q3 '22: 20K Q4 '22: 1.5M Q1 '23: 568K Q2 '23: 0 Q3 '23: 0 Q4 '23: -3.9M Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q2 '22: 250.9K Q3 '22: 137.5K Q4 '22: 1.4M Q1 '23: 343.1K Q2 '23: -174.5K Q3 '23: -183.2K Q4 '23: -4.2M Q1 '24: -304.6K Q2 '24: -353.6K Q3 '24: -235K Q4 '24: -225.4K Q1 '25: -216.8K Q2 '25: -218.7K Q3 '25: -117.9K Q4 '25: -126.5K Q1 '26: -69.1K Q2 '26: -99.1K Q3 '26: -135.7K Q4 '26: -81.5K Q1 '27: -75.8K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Net Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q2 '22: -250.9K Q3 '22: 748.5K Q4 '22: 586.9K Q1 '23: 276.7K Q2 '23: -144.1K Q3 '23: -138.3K Q4 '23: -4.2M Q1 '24: -304.6K Q2 '24: -353.6K Q3 '24: -235K Q4 '24: -225.4K Q1 '25: -216.8K Q2 '25: -218.7K Q3 '25: -196.3K Q4 '25: -143.1K Q1 '26: -80.5K Q2 '26: -110.8K Q3 '26: -142.5K Q4 '26: -81.5K Q1 '27: -75.8K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Cost of Revenue Quarterly

0 900K 1.8M 2.7M Q1 '20: 904 Q2 '20: 3.5K Q3 '20: 3.5K Q4 '20: 8.5K Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 136K Q1 '22: 294K Q2 '22: 1M Q3 '22: 180K Q4 '22: 2M Q1 '23: 922K Q2 '23: 0 Q3 '23: 0 Q4 '23: 2.4M Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating Cash Flow Quarterly

-1.1M -700K -350K 0 350K 700K 1.1M Q2 '22: -977.3K Q3 '22: 376.8K Q4 '22: -28K Q1 '23: -28.1K Q2 '23: -57.6K Q3 '23: 2.5K Q4 '23: 5.6K Q1 '24: -27.9K Q2 '24: 188 Q3 '24: -4.5K Q4 '24: -2.6K Q1 '25: -4K Q2 '25: -2.4K Q3 '25: -6.4K Q4 '25: -1.8K Q1 '26: -787 Q2 '26: -1.2K Q3 '26: -839 Q4 '26: 124 Q1 '27: 6.1K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Free Cash Flow Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 80M 160M 240M Q3 '20: 10.9M Q1 '21: 10.9M Q2 '21: 52.4M Q3 '21: 54.5M Q1 '22: 205.4M Q2 '22: 205.5M Q3 '22: 205.5M Q1 '23: 206.5M Q2 '23: 206.5M Q3 '23: 206.5M Q1 '24: 207M Q2 '24: 207M Q3 '24: 207M Q1 '25: 207M Q2 '25: 207M Q3 '25: 207M Q1 '26: 207M Q2 '26: 207M Q3 '26: 207M Q1 '27: 207M Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q1 '26 Q1 '27

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.02 -0.01 -0.01 0.00 0.01 0.01 0.02 Q1 '20: 0.00 Q4 '20: 0.00 Q1 '21: 0.00 Q2 '21: 0.00 Q3 '21: 0.00 Q4 '21: 0.00 Q4 '23: -0.02 Q1 '24: -0.02 Q2 '24: -0.02 Q3 '24: -0.02 Q4 '24: -0.01 Q1 '25: -0.01 Q2 '25: -0.01 Q3 '25: -0.01 Q4 '25: 0.00 Q1 '26: 0.00 Q2 '26: 0.00 Q3 '26: 0.00 Q4 '26: 0.00 Q1 '27: 0.00 Q4 '20 Q3 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.